secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGILE THERAPEUTICS INC (—)
CIK:        0001261249
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001558370-23-016195
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Agile Therapeutics receives Nasdaq delisting notice for failing stockholder equity compliance
--------------------------------------------------------------------------------

- Nasdaq notified Agile (AGRX) on Sept 27, 2023 that it failed to comply with $2.5M equity rule extension; delisting to proceed unless appealed.
- Agile intends to request a hearing before Nasdaq Hearings Panel, which will stay delisting pending outcome.
- Panel may grant up to 180 additional days (until March 25, 2024) to regain compliance; no assurance of success.
- Delisting could significantly reduce liquidity, market price, and ability to raise capital for the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1261249/000155837023016195/0001558370-23-016195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1261249/000155837023016195/agrx-20230927x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer